PTC Therapeutics Company Profile (NASDAQ:PTCT)

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTCT
  • CUSIP: N/A
  • Web:
  • Market Cap: $432.04 million
  • Outstanding Shares: 34,316,000
Average Prices:
  • 50 Day Moving Avg: $11.99
  • 200 Day Moving Avg: $11.83
  • 52 Week Range: $4.03 - $16.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.96
  • P/E Growth: 0.38
Sales & Book Value:
  • Annual Revenue: $90.36 million
  • Price / Sales: 4.78
  • Book Value: $2.94 per share
  • Price / Book: 4.28
  • EBIDTA: ($114,520,000.00)
  • Net Margins: -236.68%
  • Return on Equity: -90.33%
  • Return on Assets: -50.69%
  • Debt-to-Equity Ratio: 0.69%
  • Current Ratio: 5.74%
  • Quick Ratio: 5.74%
  • Average Volume: 1.25 million shs.
  • Beta: 1.38
  • Short Ratio: 2.95

Frequently Asked Questions for PTC Therapeutics (NASDAQ:PTCT)

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.03. The company earned $26.50 million during the quarter, compared to the consensus estimate of $27.93 million. PTC Therapeutics had a negative return on equity of 90.33% and a negative net margin of 236.68%. PTC Therapeutics's revenue was up 40.2% on a year-over-year basis. During the same period last year, the company earned ($1.22) earnings per share. View PTC Therapeutics' Earnings History.

Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?

9 brokers have issued 1-year price targets for PTC Therapeutics' shares. Their predictions range from $7.00 to $25.00. On average, they anticipate PTC Therapeutics' stock price to reach $14.25 in the next twelve months. View Analyst Ratings for PTC Therapeutics.

What are analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:

  • 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (5/11/2017)
  • 2. Cowen and Company analysts commented, "PTCT announced 4Q16 results today: Translarna EU sales continue to grow." (3/16/2017)
  • 3. Royal Bank of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)
  • 4. Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)

Who are some of PTC Therapeutics' key competitors?

Who owns PTC Therapeutics stock?

PTC Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.91%), State Street Corp (5.53%), Boxer Capital LLC (4.37%), Frontier Capital Management Co. LLC (3.90%), Camber Capital Management LLC (3.64%) and Wellington Management Group LLP (3.08%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, David P Southwell, Dawn Svoronos, Mark Elliott Boulding, Mark Rothera, Neil Gregory Almstead, Richard Aldrich and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?

PTC Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Nomura Holdings Inc., Tocqueville Asset Management L.P., Morgan Stanley, Teachers Advisors LLC, FMR LLC, Bogle Investment Management L P DE and Parametric Portfolio Associates LLC. View Insider Buying and Selling for PTC Therapeutics.

Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?

PTC Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, State Street Corp, Camber Capital Management LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., Chicago Equity Partners LLC, Columbus Circle Investors and Spark Investment Management LLC. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.

How do I buy PTC Therapeutics stock?

Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PTC Therapeutics stock cost?

One share of PTC Therapeutics stock can currently be purchased for approximately $12.59.

Analyst Ratings

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $14.25 (13.19% upside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Royal Bank of CanadaSet Price TargetHold$12.00HighView Rating Details
3/22/2017Barclays PLCReiterated RatingEqual Weight$13.00MediumView Rating Details
3/16/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
3/6/2017Credit Suisse Group AGReiterated RatingOutperform -> Positive$25.00N/AView Rating Details
1/10/2017Jefferies Group LLCReiterated RatingHold$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 -> $7.00N/AView Rating Details
11/11/2016Citigroup IncUpgradeNeutral -> Buy$7.00 -> $15.00N/AView Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$15.00N/AView Rating Details
10/3/2016Bank of America CorpReiterated RatingHold$15.00N/AView Rating Details
4/17/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$39.00N/AView Rating Details
10/16/2015Roth CapitalReiterated RatingHold$63.00N/AView Rating Details
6/17/2015Deutsche Bank AGReiterated RatingBuy$115.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for PTC Therapeutics (NASDAQ:PTCT)
Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Earnings History by Quarter for PTC Therapeutics (NASDAQ:PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.88)($0.85)$27.93 million$26.50 millionViewListenView Earnings Details
3/16/201712/31/2016($1.07)($0.78)$24.69 million$25.20 millionViewN/AView Earnings Details
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)$10.93 million$9.22 millionViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
2017 EPS Consensus Estimate: ($2.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.96)($0.70)($0.83)
Q2 20172($0.93)($0.38)($0.66)
Q3 20172($0.89)($0.32)($0.61)
Q4 20172($0.88)($0.80)($0.84)
(Data provided by Zacks Investment Research)


Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for PTC Therapeutics (NASDAQ:PTCT)
Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 83.66%
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Dawn SvoronosDirectorBuy25,000$13.49$337,250.00View SEC Filing  
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for PTC Therapeutics (NASDAQ:PTCT)
Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
DateHeadline logoDawn Svoronos Purchases 25,000 Shares of PTC Therapeutics, Inc. (PTCT) Stock - May 24 at 7:41 PM logoNew Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics ... - PR Newswire (press release) - May 24 at 7:40 PM logoPTC Therapeutics, Inc. (PTCT) Given Average Rating of "Hold" by Analysts - May 23 at 8:22 PM logoNew Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting - May 23 at 9:46 AM logoPTC Therapeutics, Inc. (PTCT) Downgraded by Zacks Investment Research - May 11 at 8:24 AM logoPTC Therapeutics, Inc. (PTCT) Given a $12.00 Price Target at Royal Bank of Canada - May 9 at 6:52 PM logoToday's Research Reports on Stocks to Watch: Horizon Pharma and PTC Therapeutics - May 9 at 10:59 AM logoPTC Therapeutics, Inc. (PTCT) Announces Quarterly Earnings Results, Beats Estimates By $0.18 EPS - May 8 at 8:16 PM logoWhy PTC Therapeutics Stock Is Sinking Today - May 8 at 6:43 PM logoInvestor Network: PTC Therapeutics, Inc. to Host Earnings Call - May 8 at 11:55 AM logoPTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 8 at 11:55 AM logo[$$] PTC Expects Net Price of $35,000 Annually Per Patient for Emflaza - May 8 at 11:55 AM logoThis rare disease drug’s price tag was reduced from $89,000-a-year. But that may not be enough - May 8 at 11:55 AM logoPTC Therapeutics reports 1Q loss - May 8 at 7:49 AM logo5 Stocks with Earnings Acceleration to Buy Now - May 2 at 5:11 PM logoPTC Therapeutics (PTCT) Earning Somewhat Positive News Coverage, Study Finds - May 2 at 11:40 AM logoPTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by Analysts - April 29 at 1:22 AM logoPTC Therapeutics (PTCT) Given News Sentiment Score of 0.20 - April 27 at 10:38 PM logoSomewhat Critical Press Coverage Likely to Affect PTC Therapeutics (PTCT) Share Price - April 24 at 6:28 PM logoPTC Therapeutics (PTCT) Given Coverage Optimism Score of 0.04 - April 22 at 12:59 AM logoPTC Therapeutics, Inc. (PTCT) Sees Significant Growth in Short Interest - April 21 at 11:01 AM logoPTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S. - PR Newswire (press release) - April 21 at 8:48 AM logoPTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S. - Yahoo Finance - April 21 at 12:29 AM logoPTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : April 20, 2017 - April 20 at 7:27 PM logoPTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S. - April 20 at 7:27 PM logoETFs with exposure to PTC Therapeutics, Inc. : April 19, 2017 - April 19 at 7:20 PM logoPTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : April 19, 2017 - April 19 at 9:45 AM logoPTC Therapeutics (PTCT) Given Daily News Sentiment Rating of 0.31 - April 18 at 4:14 PM logoPTC Therapeutics (PTCT) Receiving Somewhat Critical News Coverage, Report Finds - April 15 at 2:13 PM logo-$0.83 EPS Expected for PTC Therapeutics, Inc. (PTCT) This Quarter - April 13 at 9:36 AM logoPTC Therapeutics (PTCT) Announces Departure of CFO, Shane Kovacs - - April 12 at 1:43 PM logoPTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs - April 10 at 6:54 PM logoPTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Analysts - April 6 at 9:58 AM logoPTC Therapeutics (PTCT) Active as Sanders and Cummings Request Info on Deflazacourt - - March 24 at 8:12 AM logoPTC THERAPEUTICS, INC. Financials - March 22 at 7:19 PM logoBernie Sanders thinks this $89,000-a-year drug should be $1,000 a year - March 22 at 7:19 PM logoU.S. lawmakers seek pricing info on PTC Therapuetics' Duchenne drug - March 22 at 7:19 PM logoBarclays PLC Reaffirms "Equal Weight" Rating for PTC Therapeutics, Inc. (PTCT) - March 22 at 8:41 AM logoPTC Therapeutics' (PTCT) "Hold" Rating Reiterated at Cowen and Company - March 22 at 8:13 AM logoKnopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers - March 21 at 10:47 AM logoREFILE-PTC Therapeutics to buy Marathon's controversial DMD drug - March 17 at 1:11 AM logoBlasted for high price of old MD drug, Marathon sells rights - March 17 at 1:11 AM logo[$$] Marathon Sells Muscular-Dystrophy Drug After Pricing Scrutiny - March 17 at 1:11 AM logoWhy PTC Therapeutics Stock Is Crashing Today - March 17 at 1:11 AM logoPRESS DIGEST - Wall Street Journal - March 17 - March 17 at 1:11 AM logoBUZZ-US STOCKS ON THE MOVE-Oracle, GoPro, PTC Therapeutics, Guess - Nasdaq - March 16 at 8:09 PM logoPTC Therapeutics will buy Marathon Pharma's controversial DMD drug for $75 mln cash, $65 million in PTC stock - MarketWatch - March 16 at 8:09 PM logo[$$] Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny - March 16 at 8:08 PM logoPTC Therapeutics, Inc. (PTCT) Releases Earnings Results, Beats Expectations By $0.29 EPS - March 16 at 10:43 AM logoPTC Therapeutics reports 4Q loss - Yahoo Finance - March 16 at 8:24 AM



PTC Therapeutics (PTCT) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff